Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Cost-effectiveness and cost-utility of add-on, low-dose prednisolone in patients with rheumatoid arthritis aged 65+:The pragmatic, multicenter, placebo-controlled GLORIA trial

Autor: L Hartman, M El Alili, M Cutolo, D Opris, JAP Da Silva, Z Szekanecz, F Buttgereit, P Masaryk, R Bos, MR Kok, S Paolino, VMH Coupé, WF Lems, M Boers

Publikováno v: GLORIA consortium 2022, ' Cost-effectiveness and cost-utility of add-on, low-dose prednisolone in patients with rheumatoid arthritis aged 65+ : The pragmatic, multicenter, placebo-controlled GLORIA trial ', Seminars in Arthritis and Rheumatism, vol. 57, 152109 . https://doi.org/10.1016/j.semarthrit.2022.152109
Seminars in Arthritis and Rheumatism, 57:152109. W.B. Saunders Ltd

© 2022Background: The GLORIA placebo-controlled trial found a favorable balance of benefit and harm for two years of prednisolone (5 mg/day) as add-on treatment for rheumatoid arthritis (RA) patients aged 65+. This study evaluated the cost-effective

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3086d7a9723b67930b5c7b45e596eabd
https://research.vumc.nl/en/publications/cebe6386-07bb-4da6-b62a-c3c5673a2f6e

Efficacy and safety of selective glucocorticoid receptor modulators in comparison to glucocorticoids in arthritis, a systematic review.

Autor: M Safy, M J H de Hair, J W G Jacobs, F Buttgereit, M C Kraan, J M van Laar

Publikováno v: PLoS ONE, Vol 12, Iss 12, p e0188810 (2017)

Long-term treatment with glucocorticoids (GCs) plays an important role in the management of arthritis patients, although the efficacy/safety balance is unfavorable. Alternatives with less (severe) adverse effects but with good efficacy are needed. Se

Externí odkaz: https://doaj.org/article/de2bd3634aa04a06912705763f94dc7c

CD73 and CD29 concurrently mediate the mechanically induced decrease of migratory capacity of mesenchymal stromal cells

Autor: A Ode, J Kopf, A Kurtz, K Schmidt-Bleek, P Schrade, P Kolar, F Buttgereit, K Lehmann, DW Hutmacher, GN Duda, G Kasper

Publikováno v: European Cells & Materials, Vol 22, Pp 26-42 (2011)

The assumption that mesenchymal stromal cell (MSC)-based-therapies are capable of augmenting physiological regeneration processes has fostered intensive basic and clinical research activities. However, to achieve sustained therapeutic success in vivo

Externí odkaz: https://doaj.org/article/38b5bd78c1c5433a99ca04575113ff78

Orale Glukokortikoide

Autor: C. Strehl, F. Buttgereit, D. Freier

Publikováno v: Zeitschrift für Rheumatologie. 78:775-788

Glucocorticoids (GC) have been proven drug substances in rheumatology for more than 70 years. They act very rapidly in high doses through membrane stabilizing effects. Genomic therapeutic effects of GC even in very low doses are mainly due to inhibit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c11011c61a0e828d08f8e9499ae07e0
https://doi.org/10.1007/s00393-019-00697-y